Thymidine phosphorylase expression correlates with malignant potential and anti-tumor effect of doxifluridine on gastric cancer: Multivariate analysis for adjuvant chemotherapy doxifluridine vs. 5-fluorouracil

Oncology Reports

Volumn 10, Issue 5, 2003, Pages 1105-1111

  Takiguchi, Nobuhiro ^a,b   Ishii, Rumiko ^a   Koda, Keiji ^a   Oda, Kenji ^a   Miyazaki, Masaru ^a  

^a CHIBA UNIVERSITY   (Japan)

^b CHIBA CANCER CENTER   (Japan)

Author keywords

5 fluorouracil; Adjuvant chemotherapy; Doxifluridine; Gastric cancer; Thymidine phosphorylase

Indexed keywords

ANTINEOPLASTIC ANTIMETABOLITE; DOXIFLURIDINE; FLOXURIDINE; FLUOROURACIL; THYMIDINE PHOSPHORYLASE;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ARTICLE; BIOSYNTHESIS; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; METABOLISM; METASTASIS; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; PROGNOSIS; RISK; STOMACH TUMOR; TIME;

ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; CHEMOTHERAPY, ADJUVANT; FEMALE; FLOXURIDINE; FLUOROURACIL; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM METASTASIS; PROGNOSIS; RISK; STOMACH NEOPLASMS; THYMIDINE PHOSPHORYLASE; TIME FACTORS;

EID: 2142746398     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.10.5.1105     Document Type: Article

References (28)

1. Cook AF, Holman MJ, Kramer MJ and Trown PW: Fluorinated pyrimidine nucleosides: synthesis and antitumor activity of a series of 5′-deoxy-5-fluoropyrimidine nucleosides. J Med Chem 22: 1330-1335, 1979. (Pubitemid 10193598)
2. Miwa M, Ura M, Nishida M, Sawada N, Ishikawa T, Mori K, Shimma N, Umeda I and Ishitsuka H: Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumors by enzymes concentrated in human liver and cancer tissue. Eur J Cancer 34: 1274-1281, 1998. (Pubitemid 28342121)
3. Niitani H, Kimura K, Saito T, Nakao I, Abe O, Urushizaki I, Ohta K, Yoshida Y, Kimura T and Kurihara M: Phase II study of 5′-deoxy-5- fluorouridine (5′-DFUR) on patients with malignant cancer - multi-institutional cooperative study. Jpn J Cancer Chemother 12: 2044-2051, 1985. (Pubitemid 17215003)
4. Ishitsuka H, Miwa M, Takemoto K, Fukuoka K, Itoga A and Maruyama H: Role of uridine phosphorylase for antitumor activity of 5′-deoxy-5- fluorouridine. Gann 71: 112-123, 1980. (Pubitemid 10100453)
5. Kono A, Hara Y, Sugata S, Kurube Y, Matsushima Y and Ishitsuka H: Activation of 5′-deoxy-5-fluorouridine by thymidine phosphorylase in human tumors. Chemo Pharm Bull 31: 175-178, 1983. (Pubitemid 13122231)
6. Eda H, Fujimoto K, Watanabe S, Ura M, Hino A, Tanaka Y, Wada K and Ishitsuka H: Cytokines induce thymidine phosphorylase expression in tumor cells and make them more susceptible to 5′-deoxy-5-fluorouridine. Cancer Chemother Pharmacol 32: 333-338, 1993. (Pubitemid 23207988)
7. Koizumi W, Saigenji K, Nakamaru N, Okayasu I and Kurihara M: Prediction of response to 5′-deoxy-5-fluorouridine (5′-DFUR) in patients with inoperable advanced gastric cancer by immunostaining of thymidine phosphorylase/platelet-derived endothelial cell growth factor. Oncology 56: 215-222, 1999. (Pubitemid 29161291)
8. Yamamoto Y, Toi M and Tominaga T: Prediction of the effect of 5′-deoxy-5-fluorouridine by the status of angiogenic enzyme thymidine phosphorylase expression in recurrent breast cancer patients. Oncol Rep 3: 863-865, 1996. (Pubitemid 26323740)
9. Ishii R, Takiguchi N, Oda K, Koda K and Miyazaki M: Thymidine phosphorylase expression is useful in selecting adjuvant chemotherapy for stage III gastric cancer. Int J Oncol 19: 717-722, 2001.
10. Furukawa T, Yoshimura A, Sumizawa T, Haraguchi M and Akiyama S: Angiogenic factor. Nature 356: 668, 1992.
11. Takebayashi Y, Miyadera K, Akiyama S, Hokita S, Yamada K, Akiba S, Yamada Y, Sumizawa T and Aikou T: Expression of thymidine phosphorylase in human gastric carcinoma. Jpn J Cancer Res 87: 288-295, 1996. (Pubitemid 26117060)
12. Maeda K, Chung YS, Ogawa Y, Takatsuka S, Kang SM, Ogawa M, Sawada T, Onoda N, Kato Y and Sowa M: Thymidine phosphrylase/platelet-derived endotherial cell growth factor expression associated with hepatic metastasis in gastric carcinoma. Br J Cancer 73: 884-888, 1996. (Pubitemid 26116738)
13. Takiguchi N, Nakajima N, Saitoh N, Fujimoto S and Nakazato H: A phase III randomized study comparing oral doxifluridine and oral 5-fluorouracil after curative resection of gastric cancer. Int J Oncol 16: 1021-1027, 2000.
14. Japanese Research Society for Gastric Cancer: The general rules for the gastric cancer study in surgery and pathology. Jpn J Surg 11: 127-145, 1981.
15. Sobin LH and Wittekind CH (eds): UICC TNM Classification of malignant tumors. 5th edition. John Wiley & Sons, Inc., New York, 1997.
16. Nishida M, Hino A, Mori K, Matsumoto T, Yoshikubo T and Ishitsuka H: Preparation of anti-human thymidine phosphorylase monoclonal antibodies useful for detecting the enzyme levels in tumor tissues. Biol Pharm Bull 19: 1407-1411, 1996. (Pubitemid 26403242)
17. Blum JL, Jones SE, Buzdar AU, LoRusso PM, Kuter I, Vogel C, Osterwalder B, Burger HU, Brown CS and Griffin T: Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol 17: 485-493, 1999. (Pubitemid 29075232)
18. Twelves C: Capecitabine as first-line treatment in colorectal cancer: pooled data from two large, phase III trials. Eur J Cancer 38 (Suppl. 2): 15-20, 2002.
19. Ishikawa T, Sekiguchi F, Fukase Y, Sawada N and Ishitsuka H: Positive correlation between the efficacy of capecitabine and deoxifuluridine and the ratio of thymidine phospholylase to dihydropyrimidine dehydrogenase activities in tumors in human cancer xenografts. Cancer Res 58: 685-690, 1998. (Pubitemid 28099478)
20. Ju J, Kane SE, Lenz HJ, Danenbarg KD, Chu E and Danenberg PV: Desensitization and sensitization of cells to fluoropyrimidines with different antisenses directed against thymidilate synthase messenger RNA. Clin Cancer Res 4: 2229-2236, 1998. (Pubitemid 28415671)
21. Hermans J, Bonenkamp JJ, Boon MC, Bunt AM, Ohyama S, Sasako M and van de Velde CJ: Adjuvant therapy after curative resection for gastric cancer: a meta-analysis of randomized trials. J Clin Oncol 11: 1441-1447, 1993. (Pubitemid 23228247)
22. Nakajima T, Ota K, Ishihara S, Oyama S, Nishi M and Hamashima N: Meta-analysis of 10 postoperative adjuvant chemotherapies for gastric cancer in CIH. Jpn J Cancer Chemother 21: 1800-1805, 1994. (Pubitemid 24315580)
23. Imanaga H and Nakazato H: Three prospective controlled studies. Part 1. Rinsyou Geka (in Japanese) 36: 175-183, 1981.
24. Nakajima T, Takahashi T, Takagi K, Kuno K and Kajitani T: Comparison of 5-fluorouracil with ftorafur in adjuvant chemotherapies with combined inductive and maintenance thearapies for gastric cancer. J Clin Oncol 2: 1366-1371, 1984. (Pubitemid 15186146)
25. Inokuchi K, Hattori T, Taguchi T, Abe O and Ogawa N: Postoperative adjuvant chemotherapy for gastric carcinoma. Analysis of data on 1805 patients followed for 5 years. Cancer 53: 2393-2397, 1984. (Pubitemid 14102475)
26. Shirasaka T, Shimamato Y, Ohshimo H, Yamaguchi M, Kato T, Yonekura K and Fukushima M: Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anticancer Drugs 7: 548-557, 1996. (Pubitemid 26276346)
27. Ota K, Taguchi T and Kimura K: Report on nationwide pooled data and cohort investigation in UFT phase II study. Jpn J Cancer Chemother 14: 2749-2757, 1987. (Pubitemid 18015129)
28. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J and Norton L: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344: 783-792, 2001. (Pubitemid 32222155)